Browse ANXA5

Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00191 Annexin
Function

This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade.

> Gene Ontology
 
Biological Process GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050878 regulation of body fluid levels
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004859 phospholipase inhibitor activity
GO:0005543 phospholipid binding
GO:0005544 calcium-dependent phospholipid binding
GO:0055102 lipase inhibitor activity
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009897 external side of plasma membrane
GO:0030055 cell-substrate junction
GO:0072562 blood microparticle
GO:0072563 endothelial microparticle
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ANXA5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ANXA5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29632186B16 Malignant MelanomaPromote immunity (T cell function)Fusion of ANXA5 to pMHC augments lymphocyte activation by several orders of magnitude (>1,000-fold), bypasses the need for costimulation, and breaks tolerance against a model self-antigen in vivo.
29574275Malignant Ovarian NeoplasmPromote immunityThe fusion protein combines annexin V (ANXA5), an ovarian tumor and tumor vasculature targeting protein, with mutated cystathionine gamma-lyase (mCTH), an enzyme that converts selenomethionine (SeMet) into toxic methylselenol, which generates reactive oxygen species and eventual tumor cell death.
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ANXA5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ANXA5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0310.932
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1750.967
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.180.953
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0580.876
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3580.87
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3250.911
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4450.43
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2430.928
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7260.813
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3240.901
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.670.869
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1260.324
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ANXA5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ANXA5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ANXA5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ANXA5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ANXA5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ANXA5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolANXA5
Nameannexin A5
Aliases ENX2; ANX5; HEL-S-7; RPRGL3; CBP-I; VAC-alpha; anchorin CII; annexin V; annexin-5; calphobindin I; endonexin ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ANXA5 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ANXA5.
ID Name Drug Type Targets #Targets
DB02497L-Alpha-GlycerophosphorylserineSmall MoleculeANXA51
DB02846L-thioprolineSmall MoleculeANXA51
DB02929K201Small MoleculeANXA51
DB03484L-Alpha-GlycerophosphorylethanolamineSmall MoleculeANXA51
DB039351,4-Dideoxy-O2-Sulfo-Glucuronic AcidSmall MoleculeANXA5, FGF22
DB03959N,O6-Disulfo-GlucosamineSmall MoleculeANXA5, FGF1, FGF2, HGF, HS3ST3A15
DB039811,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic AcidSmall MoleculeANXA5, FGF2, HS3ST3A13
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141